The U.S. Food and Drug Administration cleared CoolSculpting, Allergan PLC's nonsurgical fat removal procedure, to treat the area below the jawline.

The approval also includes the expanded use of CoolSculpting to treat patients with a body mass index of up to 46.2 in the areas below their chin and jawline.

The Irish company said the regulator's approval was backed by the results of a 22-week clinical study in which CoolScupting reduced fat layer thickness by an average of 33% after two treatments.

Allergan's CoolSculpting selectively reduces unwanted fat through a patented cooling technology that gently cools targeted fat cells in the body, triggering a natural and controlled elimination of fat cells.